PT-141 Research Profile (2026): The Melanocortin Agonist That Acts on the Brain
A long-form research profile of PT-141 (bremelanotide) — the centrally-acting melanocortin-receptor agonist with an FDA-approved pharmaceutical identity. Discovery from a tanning peptide, structure, mechanism, and status.
PT-141 has one of the more unusual origin stories in the research-peptide catalog: it began as a byproduct of a tanning compound. Researchers studying melanotan II — a peptide designed to stimulate skin pigmentation — noticed that its metabolite produced a distinct, unexpected effect mediated through the brain rather than the skin. That observation spun off into an entirely separate research program and, eventually, an FDA-approved drug. This profile traces PT-141's discovery, its cyclic structure, its centrally-acting mechanism, and where the research stands in 2026 — for laboratory research use only.
Framing up front: The approved drug bremelanotide (brand name Vyleesi) is a prescription medication. Research-grade PT-141 sold by chemical suppliers is not that approved product. Everything below describes the published science, not guidance for human use, and there are no therapeutic or outcome claims here.
What PT-141 is
PT-141, also known as bremelanotide, is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors — principally MC4R, with activity also at MC1R. The melanocortin system is an ancient signaling network involved in a surprisingly broad set of physiological functions: pigmentation, inflammation, energy balance, and — relevant here — central pathways tied to sexual arousal.
The defining structural feature is that PT-141 is cyclic: part of the peptide backbone is closed into a ring. Cyclization locks the molecule into a constrained three-dimensional shape, which improves both its stability against enzymatic degradation and its binding fit at the melanocortin receptors. This is a recurring theme in peptide medicinal chemistry — a cyclic constraint can turn a floppy, quickly-degraded linear sequence into a stable, selective binder.
| Property | Value |
|---|---|
| Class | Cyclic melanocortin-receptor agonist |
| Other name | Bremelanotide |
| Structure | Cyclic heptapeptide |
| Molecular formula | C₅₀H₆₈N₁₄O₁₀ |
| Molecular weight | ~1025 g/mol |
| Primary receptor | MC4R (melanocortin-4 receptor) |
| Regulatory status (US) | FDA-approved (Vyleesi) for HSDD in premenopausal women |
Discovery: a metabolite that acted on the brain
The PT-141 story begins with melanotan II, a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) developed at the University of Arizona to study pigmentation. As researchers characterized melanotan II, they observed that it — and specifically its metabolite — produced central effects on sexual-arousal pathways that were clearly distinct from, and unrelated to, its action on skin pigment cells.
That metabolite became PT-141. The insight was that you could separate the two functions: strip away the pigmentation focus and isolate the centrally-mediated melanocortin signaling. Palatin Technologies took the compound forward as bremelanotide, and after a long development arc it received FDA approval in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. That approval gives PT-141 — like tesamorelin in the GH family — a registered pharmaceutical identity that most research peptides lack. Its relationship to its parent is covered further in our melanotan II research profile.
Mechanism: central, not vascular
The single most important fact about PT-141's mechanism is that it acts on the central nervous system, not the vasculature. This is what made it scientifically interesting as a distinct approach.
The well-known sexual-health drugs — sildenafil and the other PDE5 inhibitors — work peripherally. They modulate the vascular system to affect blood flow, downstream of arousal signaling. PT-141 works upstream and centrally: by agonizing MC4R in hypothalamic pathways, it engages the neural circuitry of arousal itself rather than the plumbing it eventually drives. In research framing, that means PT-141 and PDE5 inhibitors are not variations on a theme — they intervene at entirely different points in the chain, through unrelated molecular targets.
MC4R is the same receptor implicated in energy balance and appetite, which is why melanocortin agonists are studied across such a wide physiological range. PT-141's relative emphasis on the arousal-related signaling — as opposed to the pigmentation-related MC1R activity that dominates melanotan II — is what distinguishes it functionally from its non-selective parent.
What the research has examined
PT-141's literature is notable for spanning preclinical work through registrational clinical trials.
- Sexual-arousal and libido endpoints. The core research program, examined in both male and female research populations, and the basis for the clinical trials that supported approval in premenopausal women with HSDD.
- Melanocortin signaling in the CNS. Mechanistic work characterizing how MC4R agonism in the hypothalamus translates into the observed arousal-related effects, distinguishing the central route from peripheral vascular mechanisms.
- Comparative studies vs PDE5 inhibitors. Research positioning PT-141 as a mechanistically distinct alternative rather than a competitor working through the same pathway.
- Cardiovascular signal characterization. Because melanocortin agonism can influence blood pressure, the clinical program characterized cardiovascular parameters carefully — context that informs how the compound is understood and why its approved use is tightly defined.
Even with an approved indication, every application outside that narrow registered use remains research, and research-grade material carries no approved use at all.
PT-141 in the research-supplier market
In the research-compound market, PT-141 is a moderately common item — more available than truly niche neuropeptides, less ubiquitous than BPC-157. A few characteristics matter for buyers.
Because PT-141 is a cyclic peptide, its synthesis and analysis differ from those of linear sequences. The cyclization step has to be done correctly, and a real HPLC chromatogram of properly-made PT-141 reflects the cyclic product, not a linear precursor or a mixture. Mass-spec confirmation at the correct mass (~1025 Da) is therefore especially informative: it tells you the cyclization worked and the right molecule is in the vial.
PT-141 also sits in the "small market, higher per-mg cost" category that raises substitution risk — the same dynamic we flag for other lower-volume compounds. Without independent HPLC and mass spec, a buyer cannot verify what is actually in the vial. For sourcing specifics, see our PT-141 where-to-buy guide and the where-to-buy index.
Quality markers for PT-141
| Marker | What to look for |
|---|---|
| HPLC purity | ≥98% by reversed-phase HPLC, batch-specific |
| Mass spec | Observed mass ~1025 Da confirming the cyclic heptapeptide |
| Third-party testing | Janoshik, MZ Biolabs, or equivalent independent lab |
| Lyophilization | Uniform white cake, no discoloration |
| Cold chain | Refrigerated transit |
| Documentation | Batch-specific COA tied to your lot |
See our guide to reading a peptide COA for how to evaluate the paperwork.
Storage and handling
Lyophilized PT-141 is stable refrigerated at 2-8°C, with long-term storage better at -20°C. Reconstituted in bacteriostatic water, solutions are typically handled within a few weeks under refrigeration, avoiding freeze-thaw cycling. These are general handling parameters consistent with published stability data, not protocol guidance.
Bottom line
PT-141 is the melanocortin agonist that proved a research-byproduct could become a drug. Spun out of melanotan II as a metabolite that acted on the brain rather than the skin, it isolated central MC4R signaling and became — under the name bremelanotide — an FDA-approved compound with a mechanism entirely unlike the vascular PDE5 inhibitors. Its cyclic structure, its central site of action, and its tightly-defined approved use are the three facts worth carrying away.
For laboratory sourcing, treat the cyclization as something to verify: insist on batch-specific HPLC at ≥98% and mass-spec confirmation of the correct cyclic mass, plus cold-chain handling. Among US suppliers carrying PT-141 with that documentation, ROEHN Research is the one we point researchers toward.
For research use only. The approved drug and research-grade material are not the same product; nothing here is therapeutic advice.
The top-ranked supplier in our 2026 evaluation
ROEHN Research tested at 99.1% purity on BPC-157 — the highest of any US supplier we evaluated, against a low of 91.3%. Readers save 15% on a first order with code FREE15.
- Cold-chain shipped
- Batch CoA in every box
- 30-day re-test policy
- 98%+ verified purity
Get the full 38-sample purity report by email.
Eight US suppliers, thirty-eight samples, one blinded analytical lab. Every chromatogram, COA, and supplier score — delivered the moment you subscribe.
PDF delivered instantly. No account required. Unsubscribe anytime.
PT-141 Melanocortin Mechanism (2026): How MC4R Signals in the Brain
A molecular-level look at how PT-141 (bremelanotide) works — agonism at the MC4 melanocortin receptor, Gs/cAMP coupling in hypothalamic neurons, and why a central mechanism is fundamentally different from peripheral vascular drugs. Research-use framing throughout.
Melanotan II vs PT-141: A Research Comparison (2026)
Parent and metabolite, side by side. How the non-selective melanocortin agonist melanotan II compares with its centrally-acting descendant PT-141 — receptor selectivity, the regulatory split, and why their structural closeness makes mass-spec identity confirmation essential. Framed for laboratory research.
Melanotan II Research Profile (2026): The Non-Selective Melanocortin Analog
A long-form research profile of melanotan II — the synthetic alpha-MSH analog studied in pigmentation research and the parent compound of PT-141. Discovery, cyclic structure, mechanism, and an honest read on its status.